Navigation Links
NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
Date:11/3/2010

LAWRENCE, Mass., Nov. 3, 2010 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has expanded its Medisystems® in-center product portfolio to include Vasc-Alert's automated vascular access surveillance product. Pursuant to the terms of the strategic Agreement with Vasc-Alert LLC, the service can be purchased exclusively from NxStage in the United States.  

Vasc-Alert, a patented medical device, uses computer technology to analyze standard treatment data taken during each patient's scheduled hemodialysis treatments to screen for vascular access dysfunction. By monitoring the data for increasing pressure trends, Vasc-Alert identifies patients who are at risk of developing a stenosis that may decrease the effectiveness of treatment or put the access site at risk of thrombosis—a blockage that prevents the flow of blood through the access and can precipitate significant medical interventions such as thrombectomy and access revision. Weekly reports that identify at-risk patients are issued to the dialysis provider and allow the dialysis staff to proactively schedule further testing on the access. Earlier detection of access issues has the potential to lead to improved access patency, fewer hospitalizations, fewer missed treatments, and less pain, anxiety and inconvenience for patients.

Vasc-Alert offers significant ease-of-use benefits to clinics and staff. In contrast to other methodologies, no staff time is consumed in performing access surveillance testing and patient treatments are not impacted in any way.  Importantly, the readily accessible reports enable centers to comply with recent Centers for Medicare & Medicaid Services (CMS) access surveillance requirements.

"Complications in vascular access are common, and are a top concern in delivering the best care to patients," said John Kennedy, President of Vasc-Alert. "A growing number of centers have experienced the convenience, efficiency, and effectiveness of Vasc-Alert access surveillance.  Collaborating with a world-class leader in NxStage enables us to offer our innovative solution to a larger base of customers across the United States."

"NxStage strives to offer our customers leading, innovative products to better meet their needs in a constantly evolving environment," stated Joseph Turk, Senior Vice President of Commercial Operations of NxStage Medical. "The Vasc-Alert service complements our innovative Medisystems product line in a timely fashion, as providers are tasked with implementing recent CMS requirements for access surveillance."  

About Vasc-Alert Vasc-Alert provides proactive surveillance of hemodialysis patients' access sites by analyzing the hemodialysis machine blood flow and pressure data to derive the intra-access pressures. If the patient's access site is determined to be at risk, an alert report is issued.

Vasc-Alert uses readily available dialysis data- therefore no additional staff time is required for data collection. An analysis is performed for each dialysis session and trends are established for each patient. This unique trending can indicate when a patient's pressure is increasing, which may signify a problem in the access. An Alert is issued once increased pressure is detected for three consecutive treatments (KDOQI guidelines).

About NxStage Medical NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Kristen K. Sheppard, Esq. Investor Relations ksheppard@nxstage.com
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... LONDON , January 18, 2017 ... community to share research resources, has opened its first North ... . ... This marks an expansion for Ximbio following its launch in ... Cancer Research Technology (CRT), the commercialization arm of the foundation ...
(Date:1/18/2017)... China,s National Regulatory Authority Chinese Food and Drug ... Dynavax Flanders Institute Food and Drug Administration ... Gavi Alliance Glaxo Smith Klein ... Service Bureau, Japan Immune Targeting Systems ... Jenner Institute, University of oxford Johnson & Johnson ...
(Date:1/17/2017)... 2017 EU5 Glucose Monitoring Market Outlook to ... Glucose Monitoring Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Blood Glucose Meters, Blood Glucose Test Strips and Lancets. ... shares data for each of these market segements, and ...
Breaking Medicine Technology:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... SightMD – will lecture to primary eye care practitioners on the latest breakthroughs ... the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... announced its partnership with Sigfox in the U.S.A. to offer Internet ... including new offerings on large-scale environmental sensor deployments such as monitoring solutions ...
(Date:1/17/2017)... CO (PRWEB) , ... January 17, 2017 , ... ... protection and financial planning assistance to families and business professionals throughout central Colorado, ... to regional homeless families. , The Aurora Warms The Night organization is committed ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused ... study for its dental gel that shows significant reduction in plaque levels and gum ... The study was conducted at the Beckman Laser Institute at UC Irvine and has ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC ... keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, ... president, Phil Talamo, said, “We are delighted to have Sandra Lee join us ...
Breaking Medicine News(10 mins):